This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
Context. “Compound 23” (Merck) is a selective oral cathepsin K (CatK) inhibitor intended for osteoarthritis. Osteoarthritis affects around 15% of…
molecule
6 months ago ●
4 mins read
The ACS first disclosures from ACS Spring 2022 MEDI section included six molecules, summarized below. Together with industry veteran Jesse…
Article
12 months ago ●
7 mins read
Context. Obicetrapib (Monash University and NewAmsterdam Pharma) is an oral selective cholesteryl ester transfer protein (CETP) inhibitor being developed for…
molecule
6 months ago ●
5 mins read
This article reviews the three novel drugs approved by the FDA in March 2022 in detail. together with Dr. Naveed…
Article
12 months ago ●
10 mins read
Context. ACT-660602 (Idorsia Pharmaceuticals) is an oral chemokine receptor CXCR3 antagonist being developed for autoimmune diseases. Chemokines and their receptors…
molecule
6 months ago ●
3 mins read
The FDA approved five novel small molecule drugs in neurology in 2021. Addressing a range of conditions from ADHD to…
Article
1 year ago ●
14 mins read
Load More
